LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compound Discovered in Florida Keys Shows Potential as Colon Cancer Treatment

By LabMedica International staff writers
Posted on 01 Nov 2010
A chemical compound made from a type of bacteria discovered in the Florida Keys (USA) by a pharmacy researcher has shown effectiveness in fighting colon cancer in preclinical research.

Writing online October 2010 in the Journal of Pharmacology and Experimental Therapeutics, scientists from the University of Florida (UF; Gainesville, USA) reported that the compound--known as largazole because it was first discovered near Key Largo--suppresses human cancer cell growth in cultures and rodent models by attacking a class of enzymes involved in the packaging and structure of DNA.

More research is needed, but scientists hope that the finding will lead to new treatments for the about 50,000 people struck with colorectal cancer each year in the United States. Researchers are enthusiastic because in addition to having the marine bacteria as a natural source of the chemical, they have been able to produce synthetically the active chemical compound extracted from the bacteria.

"It is challenging to develop natural marine products into drug therapies due to what is termed the ‘the supply problem,'” said Dr. Hendrik Luesch, an associate professor of medicinal chemistry in the UF College of Pharmacy. "We have solved the supply problem for largazole because it has a relatively simple structure, which has made it easy to reproduce in the lab.”

The Luesch lab discovered largazole while studying samples of bacteria from the Florida Keys, publishing the finding in 2008. Known as cyanobacteria, the microbes have evolved to fend off predators or deal with harsh conditions in a marine environment, employing toxins to aid their own survival. The toxins are the compounds chemists such as Dr. Luesch desire to isolate and understand in a quest to create drugs that similarly fend off invading cancers in the body.

Since the discovery, Dr. Luesch's lab determined the compound inhibits enzymes known as histone deacetylases (HDACs), which are linked to many diseases and are increasingly viewed as promising for cancer therapy. Dr. Jiyong Hong, an assistant professor of chemistry at Duke University (Durham, NC, USA), teamed with the UF researchers to chemically reproduce the compound for additional preclinical testing, which indicates it is a potent inhibitor of cancer cells that has the right characteristics to reach its intended target without the toxic side effects of many cancer drugs.

"Knowing HDAC is the target that makes largazole effective means we can predict good drug properties because there are already two anticancer products on the market that work this way,” said Dr. Luesch, who is a member of the UF Shands Cancer Center.

Three important features make this marine compound more promising than other natural products as an effective cancer-fighting drug, Dr. Luesch noted that availability of supply, knowing its mode of action, and the fact that its cellular target is already a known anticancer target known to result in the necessary selectivity for cancer cells over normal cells.

Dr. Luesch presented the study's findings September 9, 2010, at the Marine Drug Discovery Symposium in Pohang, South Korea, and later in Mid-October at the Marine Natural Products Symposium in Phuket, Thailand. The research is planned for publication in the November 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.

Related Links:
University of Florida
Duke University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more